✦HEALTH · 30% off Purgo Labs✦

Category explainer

CBL-514 vs Retatrutide and Tirzepatide

CBL-514 is being talked about alongside the weight-loss peptides. It belongs to a different category. One is aimed at a patch of fat and the other two at body weight.

Read and checked on 17 November 2026. Research reference only. This page is not medical advice and gives no instructions for use.

CBL-514
Local injection, measured in millilitres of fat in the treated area. Phase 3, no results yet
Retatrutide
Peptide, measured in body weight. 28.3% at 80 weeks in TRIUMPH-1. Not approved
Tirzepatide
Peptide, measured in body weight. 20.9% at 72 weeks in SURMOUNT-1. Approved prescription medicine
Head to head studies
None

Two different kinds of drug

Retatrutide and tirzepatide are peptides that act on hormone receptors. They work through the whole body, mainly by changing appetite and how energy is handled, and their trials count the result in body weight.

CBL-514 is injected into fat under the skin and is meant to act there. Its trials count the result in the volume of fat in the treated area and in how the abdomen is graded on a visual scale. Caliway's protocol names curcumin and trans-resveratrol as its active ingredients, so it is not a peptide and not a GLP-1.

Side by side

CBL-514RetatrutideTirzepatide
What it isA small-molecule injection. The protocol names curcumin and trans-resveratrolA peptide that acts on three hormone receptorsA peptide that acts on two hormone receptors
Where it actsIn the fat where it is injectedThrough the whole body, by way of appetite and metabolismThrough the whole body, by way of appetite and metabolism
What the trials measureFat volume in one treated area, in millilitres, and a visual ratingBody weightBody weight
Headline result166.6 mL less abdominal fat against a 15.7 mL gain on placebo (company release, Phase 2b)28.3% lower body weight at 80 weeks on the highest strength (TRIUMPH-1)20.9% lower body weight at 72 weeks on the highest strength (SURMOUNT-1)
Largest study reported173 participants2,339 participants2,539 participants
StagePhase 3 under way, no resultsPhase 3 reported, not approvedApproved as a prescription medicine
Can a research vial be checkedNo. The formula is not publicYes, a lab can confirm the peptide and the amountYes, a lab can confirm the peptide and the amount

The headline numbers cannot be set against each other. A percentage of body weight and a volume of fat in one area are different measurements taken in different people for different lengths of time.

The difference in scale

The CBL-514 results are in the range of 150 to 170 mL of fat in the treated area. That is a visible change to one part of the body and a small one on a scale. The studies were set up to detect a change in shape.

The peptide trials are the reverse. TRIUMPH-1 followed 2,339 people for 80 weeks and SURMOUNT-1 followed 2,539 for 72 weeks, and both report total body weight. Neither tells you where on the body the change happened.

How much evidence each has

Tirzepatide has completed Phase 3 programmes and is an approved prescription medicine. Retatrutide has reported all four of its TRIUMPH Phase 3 trials and is not yet approved. Our retatrutide Phase 3 page keeps those results current.

CBL-514 has three published studies and one company release, the largest with 173 participants, all sponsored by its maker. Its two Phase 3 trials have estimated primary completion dates in mid 2027. The CBL-514 explainer has the full trial table.

What can be verified in a research vial

This is where the three part ways for anyone looking at research suppliers. A peptide has a defined sequence. An independent lab can confirm that a vial holds that peptide and measure how much, and the report can be checked with the lab. Our pages for retatrutide and tirzepatide list what to look for, and the vendor scoreboard shows which sellers publish reports that hold up.

CBL-514 is a formulation whose proportions are blacked out in the public protocol. A lab could tell you what is in a vial sold under that name. It could not tell you the vial matches the trial product. We set out what is being sold in can you buy CBL-514.

Questions

Is CBL-514 better than retatrutide or tirzepatide?

They are not measuring the same thing, so the question has no direct answer. CBL-514 trials report fat volume in one treated area. Retatrutide and tirzepatide trials report body weight. No study has put them side by side.

Is CBL-514 a GLP-1?

No. It does not act on the GLP-1 receptor or any hormone receptor in the published descriptions. It is a locally acting injection whose protocol names curcumin and trans-resveratrol.

Does CBL-514 lower body weight?

The trials were not designed to show that. A change of about 150 to 170 mL of fat in one area is small against total body weight. The weight-loss peptides are studied for the opposite purpose and say little about any one area.

Can CBL-514 be used together with a GLP-1?

That has not been established. A physician's summary of the Phase 3 trials says people taking GLP-1 medicines are excluded. We did not read the eligibility criteria ourselves, so treat that as reported and not confirmed.

Which of the three can be bought as a research compound and verified?

Retatrutide and tirzepatide are peptides with a known sequence, so a lab report can confirm identity and amount for a given lot. CBL-514 cannot be verified that way because the amounts in the formulation have never been published.

Sources

  1. Caliway Biopharmaceuticals, CBL-0203 protocol version 1.0, 18 October 2021, posted on ClinicalTrials.gov (NCT05234736)
  2. Lorenc ZP and others. Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction. Aesthetic Surgery Journal, 2026. PMID 42159040
  3. Caliway Biopharmaceuticals. CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints, 9 February 2025
  4. ClinicalTrials.gov. SUPREME-01, NCT07140939
  5. ClinicalTrials.gov. SUPREME-02, NCT07526974
  6. Eli Lilly. Retatrutide TRIUMPH-1 topline results, 21 May 2026
  7. Jastreboff AM and others. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022
  8. Jesse Morse MD. Summary of the CBL-514 Phase 3 programme, 17 November 2026 (source of the GLP-1 exclusion note)

Related Guides